Thomas Jefferson University Hospital

Running trials

• Recruiting

  Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

  NCT07578116· Phase 3· SWOG Cancer Research Network· Source

• Recruiting

  Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation

  NCT07615049· Phase 3· SWOG Cancer Research Network· Source

• Enrolling by invitation

  Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

  NCT07703462· Phase 1/2· n-Lorem Foundation· Source

• Recruiting

  A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

  NCT07778498· Phase 1/2· Phrontline Biopharma· Source

• Recruiting

  Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  NCT07437950· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

  NCT07220187· Phase 3· SWOG Cancer Research Network· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  NORM-HF Pivotal Study

  NCT07574593· Foundry Innovation & Research 1, Limited (FIRE1)· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy

  NCT07436364· Early phase 1· Thomas Jefferson University· Source

• Recruiting

  The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

  NCT07027306· AO Foundation, AO Spine· Source

• Recruiting

  A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  NCT07470853· Phase 1· Whitehawk Therapeutics, Inc.· Source

• Recruiting

  Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

  NCT06260891· Phase 2· University of California, San Francisco· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Intra-aortic Balloon Counterpulsation (IABC) Compliance

  NCT07402018· Thomas Jefferson University· Source

• Recruiting

  ACT With CF Self-Help Toolkit

  NCT07436351· Thomas Jefferson University· Source

• Recruiting

  Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

  NCT07234968· Thomas Jefferson University· Source

• Recruiting

  Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

  NCT06686771· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  NCT06931340· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Mozobil for Autologous Hematopoietic Stem Cell Transplantation

  NCT07188090· Phase 2· Thomas Jefferson University· Source

• Recruiting

  Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  NCT06649812· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

  NCT06955169· Phase 2· RTOG Foundation, Inc.· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Tarlatamab for People With Prostate Cancer

  NCT07111507· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

  NCT06994676· Phase 1· Crossbow Therapeutics, Inc.· Source

• Recruiting

  Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

  NCT06850623· Phase 2· EXACT Therapeutics AS· Source

• Recruiting

  High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

  NCT06992427· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Home Blood Transfusions

  NCT07121140· Thomas Jefferson University· Source

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  MMA Embolization for Refractory Chronic Migraine

  NCT06735833· Cerenovus, Part of DePuy Synthes Products, Inc.· Source

• Recruiting

  Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

  NCT06957366· McMaster University· Source

• Recruiting

  Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Recruiting

  A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

  NCT06680830· Phase 2· Neuron23 Inc.· Source

• Recruiting

  A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

  NCT06562543· Phase 4· Takeda· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· AbbVie· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

Showing 50 of 247.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer9 recruiting
• Ovarian cancer8 recruiting
• Prostate cancer8 recruiting
• Acute myeloid leukaemia7 recruiting
• Multiple myeloma6 recruiting
• Childhood cancers5 recruiting
• Endometrial cancer5 recruiting
• Bladder cancer4 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Head and neck cancer4 recruiting
• Heart failure4 recruiting
• Myelodysplastic syndromes4 recruiting
• Sarcoma4 recruiting
• Triple-negative breast cancer4 recruiting
• Metastatic breast cancer3 recruiting
• Pancreatic cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Amyloidosis2 recruiting
• Atrial fibrillation2 recruiting
• Brain aneurysm2 recruiting
• Colorectal cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Kidney cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic stenosis1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Myasthenia gravis1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sickle cell disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

  NCT06701526· Phase 4· H. Lundbeck A/S· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  MBC Physical Activity Study

  NCT06500858· Thomas Jefferson University· Source

• Terminated

  A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  NCT06256484· Phase 1· Atara Biotherapeutics· Source

• Completed

  A Prolonged Nightly Fasting for Men on ADT for PCa

  NCT07462403· Thomas Jefferson University· Source

• Completed

  A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

  NCT05963984· Phase 2· Carrick Therapeutics Limited· Source

• Completed

  A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

  NCT06292923· Phase 2· Tiziana Life Sciences LTD· Source

• Recruiting

  Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

  NCT05677100· Procyrion· Source

• Terminated

  PArtial REbreathing for Migraine With Aura 1

  NCT05546385· Rehaler· Source

• Completed

  ACT with NMOSD Patients and Caregivers Pilot Study

  NCT05840055· Thomas Jefferson University· Source

• Completed

  A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

  NCT05459129· Phase 1/2· Hoffmann-La Roche· Source

• Withdrawn

  Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD

  NCT05661435· Strados Labs, Inc.· Source

• Terminated

  Culturally Tailored Educational Video to Promote Lung Cancer Screening in Vulnerable Communities

  NCT06010355· Thomas Jefferson University· Source

• Completed

  Improving Patient Experience: BMBA

  NCT05690230· Thomas Jefferson University· Source

• Completed

  Nursing-Driven Primary Palliative Care for Urban-Dwelling African Americans With Chronic Lung Disease

  NCT05611125· Thomas Jefferson University· Source

• Completed

  GCC Agonist Signal in the Small Intestine

  NCT05107219· Phase 1· University of Wisconsin, Madison· Source

• Terminated

  Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

  NCT04936230· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

  NCT05441501· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  Abbott i-STAT High Sensitivity Troponin I Study

  NCT05629572· Abbott Point of Care· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

  NCT05463744· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

  NCT05462756· Phase 3· Eli Lilly and Company· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  FREEZE-AFIB Post-Market Study

  NCT05089877· AtriCure, Inc.· Source

• Terminated

  Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT05237284· Phase 2· Sanofi· Source

• Completed

  Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

  NCT05216250· Phase 2· AbbVie· Source

• Completed

  Financial Difficulty in Patients With Blood Cancer

  NCT05212233· UNC Lineberger Comprehensive Cancer Center· Source

• Completed

  Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

  NCT05084638· Phase 4· Novartis Pharmaceuticals· Source

• Withdrawn

  Evaluation of Sleep Quality in Head and Neck Cancer Patients Throughout Treatment Course

  NCT05108233· Thomas Jefferson University· Source

• Terminated

  A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

  NCT05061420· Phase 2· Sanofi· Source

• Terminated

  A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

  NCT04914897· Phase 2· Sanofi· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Completed

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

  NCT04903626· Phase 3· AbbVie· Source

• Completed

  Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

  NCT05117541· Thomas Jefferson University· Source

• Terminated

  SPARK-ALL: Calaspargase Pegol in Adults With ALL

  NCT04817761· Phase 2/3· Institut de Recherches Internationales Servier· Source

• Terminated

  An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

  NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source

• Completed

  A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

  NCT04836559· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  FHD-286 in Subjects With Metastatic Uveal Melanoma

  NCT04879017· Phase 1· Foghorn Therapeutics Inc.· Source

• Completed

  LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

  NCT04790344· Boston Scientific Corporation· Source

• Completed

  Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

  NCT04750226· Phase 3· AbbVie· Source

• Completed

  Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues

  NCT04822688· Thomas Jefferson University· Source

• Completed

  Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy

  NCT04645004· Phase 1/2· Thomas Jefferson University· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· AbbVie· Source

• Completed

  Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

  NCT04295538· Phase 2· AbbVie· Source

• Completed

  Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  NCT04396860· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

  NCT04377555· Phase 4· Genentech, Inc.· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  NCT04173507· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

• Completed

  Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes

  NCT04264572· Thomas Jefferson University· Source

Showing 50 of 94.

Conditions

Diseases this institution publishes on or runs trials for.

• Brain aneurysm16 works · 2 trials
• Obstructive sleep apnoea15 works · 0 trials
• Sickle cell disease9 works · 3 trials
• Hydrocephalus9 works · 0 trials
• Gastroparesis3 works · 0 trials